¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"malignant transformation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • malignant myopia
    ¾Ç¼º±Ù½Ã
  • malignant smallpox
    ¾Ç¼º¸¶¸¶
  • malignant teratoma
    ¾Ç¼º±âÇüÁ¾
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • neuroleptic malignant syndrome
    ½Å°æÀÌ¿ÏÁ¦¾Ç¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • malignant hyperthermia
    ¾Ç¼º°í¿­
  • malignant fibrous histiocytoma
    ¾Ç¼º¼¶À¯Á¶Á÷±¸Á¾
  • malignant progressive histiocytoma
    ¾Ç¼ºÁøÇàÁ¶Á÷±¸Á¾
  • malignant
    ¾Ç¼º-
  • malignant acanthosis nigricans
    ¾Ç¼ºÈæ»ö°¡½Ã¼¼Æ÷Áõ
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • malignant myopia
    (¢¡degenerative myopia) º¯¼º±Ù½Ã
  • malignant smallpox
    ¾Ç¼º¸¶¸¶
  • malignant teratoma
    ¾Ç¼º±âÇüÁ¾
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant chondroid syringoma
    ¾Ç¼º¿¬°ñ¶¡°üÁ¾
  • malignant mast mast reticulosis
    ¾Ç¼ººñ¸¸¼¼Æ÷±×¹°Áõ, ¾Ç¼ººñ¸¸¼¼Æ÷¼¼¸ÁÁõ
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • borderline malignant epithelial ovarian neoplasms
    °æ°è¼º »óÇǼº ³­¼ÒÁ¾¾ç
  • fibrous histiocytoma,malignant
    ¾Ç¼º¡­ (äÂàõ¡­)
  • granuloma, malignant
    ¾Ç¼ºÀ°¾ÆÁ¾
  • histiocytoma,malignant fibrous
    Á¶Á÷±¸Á¾, ¾Ç¼º ¼¶À¯¼º
  • histiocytosis,malignant
    ¾Ç¼º
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • jaw,nonodontogenic malignant tumor
    ºñÄ¡¾Æ¼º ¾Ç¼ºÁ¾¾ç (¡­ äÂàõðþåË)
  • lues maligna => malignant syphilis
    ¾Ç¼º(äÂàõ)¸Åµ¶
  • malignant
    ¾Ç¼º(ç÷àõ)ÀÇ.
  • malignant
    ¾Ç¼º(ç÷àõ)ÀÇ
  • malignant
    ¾Ç¼ºÀÇ, (ºÏ) ¾Ç¼ºÀÇ
  • malignant Spitz nevus
    ¾Ç¼º ½ºÇÇÃ÷ ¸ð¹Ý
  • malignant acanthosis nigricans
    ¾Ç¼º Èæ»ö ±Ø¼¼Æ÷Áõ
  • malignant adenoma
    ¾Ç¼º¼±Á¾(ç÷àõàÍðþ).
  • malignant adenoma
    ¾Ç¼º¼±Á¾(¡­àÍðþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HLT heart-lung transplantation; human lipotropin; human lymphocyte transformation
LETS large external transformation-sensitive [protein]
LLETZ large loop excision of the transformation zone
LTT lactose tolerance test; leucine tolerance test; limited treadmill test; lymphocyte transformation te...
NTZ normal transformation zone
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LLETZ Large Loop Excision of the Transformation Zone
LETS Large, external, transformation-sensitive
LTT Lymphocyte Transformation Test
LBT Lymphocyte blast transformation
LT Lymphocyte transformation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • malignant granuloma
    ¾Ç¼º À°¾ÆÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾, º£°Ô³Ê À°¾ÆÁ¾°ú ´Ù¸£Áö¸¸ ±× º´ ÀÚü°¡ ¹àÇôÁöÁö ¾Ê¾Æ Á¾¾ç ¿©ºÎ Á¶Â÷µµ È®½ÇÇÏÁö ¾ÊÀºµ¥, ±«»ç¼º º´º¯ÀÌ ³Ê¹« °­ÇϹǷΠº´¸®Á¶Á÷ÇÐÀû °Ë»öµµ °ï¶õÇÏ´Ù. Àü½Å¼º ÀüÀÌ´Â ÀûÀ¸³ª ±¹¼ÒÀû ±«»ç ÁøÇàÀÌ ´ë´ÜÈ÷ ºü¸£°í ¼¼±Õ °¨¿°À» ÀÏÀ¸Å°±â ½¬¿ì¸ç ÆÐÇ÷Áõ°ú À¯»çÇÑ °£Çæ ¿­°ú °í¿­ÀÌ ÀϾ Àü½ÅÀÌ ¼è¾àÇØÁö°í ¿¹Èİ¡ ³ª»Ú´Ù.
  • malignant hemocytoblastoma
    ¾Ç¼º Ç÷±¸¸ð¼¼Æ÷Á¾
  • malignant hyperthermia
    ¾Ç¼º °í¿­Áõ, ¾Ç¼º °í¿­
    ¸¶Ãë Áß¿¡ °©ÀÚ±â °í¿­À» ³»°í »ç¸Á·üÀÌ ±ØÈ÷ ³ôÀº ÁõÈıº¿¡ ´ëÇÏ¿© À̸§ÀÌ ºÙ¿©Áø °ÍÀÌ´Ù. Áõ»óÀº È£ÈíÀ̳ª ¸Æ¹ÚÀÌ »¡¶óÁö°í ü¿ÂÀº 5ºÐ¿¡ 1¡É Á¤µµÀÇ ¼Óµµ·Î 42¡É¿¡³ª ´ÞÇÑ´Ù. µ¿½Ã¿¡ ±ÙÀÇ °æÁ÷À̳ª °ú±äÀåÀÌ »ý±â°í ´ë»ç¼º ¹× È£Èí¼º »êÁõ, °íÄ®·ýÇ÷ÁõÀÌ ³ªÅ¸³­´Ù. ±Ù°æÁ÷¼º À§Ãà, À¯ÀüÀÚ ÀÎÀÚ
  • malignant hyperthermia syndrome
    ¾Ç¼º °í¿­ ÁõÈıº
  • malignant lesion
    ¾Ç¼º º´¼Ò
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
    1. ¿ÜÀ½¿¡ »ý±â´Â °¡Àå Áß¿äÇÑ º´º¯ÀÎ Á¾¾çÀÇ ÀÏÁ¾À¸·Î ¿ÜÀ½ÀÇ ¾Ç¼º Èæ»öÁ¾Àº µå¹°°í, ¿©¼º¿¡¼­ °üÂûµÇ´Â Èæ»öÁ¾ÀÇ 2%°¡ ¿ÜÀ½¿¡¼­ ¹ß»ýÇÑ´Ù. 2. »ö¼Ò ¼¼Æ÷¿¡ »ý±ä ¾Ç¼º Á¾¾ç. 3. Ç¥ÇǼº Èæ»ö±¸¿Í ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýÇÏ´Â ´ë´ÜÈ÷ ¾Ç¼ºÀÎ Á¾¾çÀÌ´Ù. ¸ðµç ¾Ç¼º Á¾¾ç Áß 1%°¡ ¾Ç¼º Èæ»öÁ¾ÀÌ´Ù. ÀÌÁß 90%´Â ¿ÜÇÇ¿¡ ³ªÅ¸³ª°í 10%´Â ÇǺΠ¿Ü¿¡ ³ªÅ¸³­´Ù. ¸ðµç ¾Ç¼º Èæ»öÁ¾ Áß 1%´Â ±¸°­ ³»¿¡¼­ ¹ß»ýÇÑ´Ù. ¹ß»ýÀ²ÀÌ Áõ°¡µÇ´Â °Íó·³ º¸ÀÌ´Â ÀÌ·± Á¾¾çÀÇ Æ¯È÷ ³ª»Û Á¡Àº ¸²ÇÁ ¼øÈ¯°ú Ç÷¾× ¼øÈ¯À» ÅëÇØ ºü¸£°Ô ÀüÀ̵Ǵ °ÍÀÌ´Ù.
  • malignant mesenchymoma
    ¾Ç¼º ³»¹è¿±Á¾
  • malignant myopia
    ¾Ç¼º ±Ù½Ã
    Ã༺ ±Ù½Ã·Î¼­ ¾ÈÃàÀåÀÌ ±¼Àý·Â¿¡ ºñÇØ ³Ê¹« ±æ¾î ÆòÇà ±¤¼±ÀÌ ¸Á¸· ¾Õ¿¡ ÃÊÁ¡À» ¸ÎÀ¸¹Ç·Î ¼±¸íÇÏÁö ¾ÊÀº »óÀ» ¸Î°Ô µÈ´Ù. °úµµÇÑ Á¶Àý ¹× ´« ¸ðÀ½, ½Ã½Å°æ À¯µÎÀÇ ºÎÁ¾, ³»ºÐºñ ÀÌ»ó, Æí½Ä µîÀÌ ¿øÀÎÀ̶ó°í ÇÏ´Â ÁÖÀåµµ ÀÖÀ¸³ª ºÐ¸íÄ¡ ¾Ê´Ù.
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
  • malignant oxyphilic adenoma
    ¾Ç¼º È£»ê¼º ¼±Á¾
  • malignant plasma cell
    ¾Ç¼º ÇüÁú ¼¼Æ÷
  • malignant pleomorphic adenoma
    ¾Ç¼º ´ÙÇü¼º ¼±Á¾
  • malignant salivary gland tumor
    ¾Ç¼º Ÿ¾×¼± Á¾¾ç
  • malignant tumor
    ¾Ç¼º Á¾¾ç
    Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû, È­ÇÐÀû, »ý¹°ÇÐÀûÀÎ ¾Ï¿ø¼º ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç ¹«Á¦ÇÑÀÇ ¼¼Æ÷ ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§ Á¶Á÷À» ÆÄ±«, ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷ ¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ ¾Ç¾×ÁúÀ» ¾ß±â½ÃÄÑ Á×À½ÀÇ À§ÇèÀ» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
  • non-malignant
    ºñ¾Ç¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
transformation constant <physics, radiobiology> The fraction of the amount of a radionuclide that undergoes transition per unit time. Formally:
Lamda=dP/dt
Where dP is the probability of a given nucleus undergoing spontaneous nuclear transition in the time interval dt.
(16 Dec 1997)
transformation efficiency The number of bacterial cells that uptake and express plasmid DNA divided by the mass of plasmid used (in transformants/microgram).
(09 Oct 1997)
transformation, genetic The unidirectional transfer and incorporation of foreign DNA by prokaryotic or eukaryotic cells and the subsequent recombination of part or all of that DNA into the cell's genome. (glossary of genetics: classical and molecular, 5th ed)
(12 Dec 1998)
transformation zone Zone on the cervix at which squamous epithelium and columnar epithelium meet; changes location in response to a woman's hormonal status.
(05 Mar 2000)
Lobry de Bruyn-van Ekenstein transformation The conversion of glucose to fructose and mannose in dilute alkali by enolization adjacent to the carbonyl group to form an enediol, a reaction analogous to certain biochemical transformations.
(05 Mar 2000)
logit transformation A method of linearizing dose-response curves for radioimmunoassay techniques; i.e., Logit B (bound)/Bo(initial binding) = Log (B/Bo/1-B/Bo).
(05 Mar 2000)
lymphocyte transformation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
cancer, malignant melanoma A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma.
(12 Dec 1998)
canine malignant lymphoma <tumour> A progressive fatal disease of dogs characterised by neoplastic transformation and proliferation of lymphoid cells, usually originating in solid lymphoid organs (lymphosarcoma) or bone marrow (lymphocytic leukaemia).
(05 Mar 2000)
malignant <oncology> Tending to become progressively worse and to result in death. Having the properties of anaplasia, invasion and metastasis, said of tumours.
Origin: L. Malignans = acting maliciously
(18 Nov 1997)
malignant anaemia <haematology> A form of anaemia (low red blood cell counts) that results when the bone marrow fails to produce adequate numbers of red blood cells due to a deficiency in vitamin B12. Intrinsic factor, necessary for normal B12 absorption, may be the underlying cause for B12 deficiency if is not produced in the gastric glands (in the stomach).
Origin: Gr. Haima = blood
(27 Sep 1997)
malignant carcinoid syndrome <syndrome> A symptom complex associated with carcinoid tumour and characterised by attacks of severe flushing of the skin, diarrhoeal watery stools, bronchoconstriction, sudden drops in blood pressure, oedema, and ascites. The carcinoid tumours are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumour secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute carcinoid heart disease.
(12 Dec 1998)
malignant catarrh A herpes virus infection of cattle characterised by catarrhal inflammation of the upper respiratory and alimentary epithelia, keratoconjunctivitis, encephalitis and lymph node enlargement. Syn: bovine epitheliosis, snotsiekte.
(12 Dec 1998)
malignant catarrhal fever A highly fatal, sporadic disease of cattle caused by alcelaphine herpesvirus 1 (a member of the Herpesviridae family) and characterised by inflammation, ulceration, and exudation of the oral and upper respiratory mucous membranes, and sometimes eye lesions and nervous system disturbances.
Synonym: malignant catarrh of cattle.
(05 Mar 2000)
malignant catarrhal fever virus A herpesvirus of wide distribution causing malignant catarrhal fever of cattle; sheep and wildebeests harbor inapparent infections and may transmit the virus to cattle.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á